R1 RCM price target raised to $21 from $17 at Canaccord

Canaccord analyst Richard Close raised the firm’s price target on R1 RCM to $21 from $17 and keeps a Buy rating on the shares. The analyst said there was much to like with 4Q results following the disappointing 3Q and lowered guidance. The company illustrated the ability to improve performance at certain clients where onboarding issues had materialized and progress with payer reimbursement timing.